1. Shaheen B, Gonzalez M. Acne sans P. acnes. J Eur Acad Dermatol Venereol. 2013; 27:1–10.
2. Jeremy AH, Holland DB, Roberts SG, Thomson KF, Cunliffe WJ. Inflammatory events are involved in acne lesion initiation. J invest dermatol. 2003; 121:20–27.
Article
3. Mirshahpanah P, Maibach HI. Models in acnegenesis. Cutan Ocul Toxicol. 2007; 26:195–202.
Article
4. Jang YH, Lee KC, Lee SJ, Kim DW, Lee WJ. HR-1 mice: a new inflammatory acne mouse model. Ann Dermatol. 2015; 27:257–264.
Article
5. Jończyk-Matysiak E, Weber-Dąbrowska B, Żaczek M, Międzybrodzki R, Letkiewicz S, Łusiak-Szelchowska M, et al. Prospects of phage application in the treatment of acne caused by Propionibacterium acnes. Front Microbiol. 2017; 8:164.
Article
6. Jassim SA, Limoges RG. Natural solution to antibiotic resistance: bacteriophages ‘The Living Drugs’. World J Microbiol Biotechnol. 2014; 30:2153–2170.
Article
7. Marples RR. The microflora of the face and acne lesions. J Invest Dermatol. 1974; 62:326–331.
Article
8. Sandoval LF, Hartel JK, Feldman SR. Current and future evidence-based acne treatment: a review. Expert Opin Pharmacother. 2014; 15:173–192.
Article
9. Bienenfeld A, Nagler AR, Orlow SJ. Oral antibacterial therapy for acne vulgaris: an evidence-based review. Am J Clin Dermatol. 2017; 18:469–490.
Article
10. Vallerand IA, Lewinson RT, Farris MS, Sibley CD, Ramien ML, Bulloch AGM, et al. Efficacy and adverse events of oral isotretinoin for acne: a systematic review. Br J Dermatol. 2018; 178:76–85.
Article
11. Nakatsuji T, Rasochova L, Huang CM. Vaccine therapy for P. acnes-associated diseases. Infect Disord Drug Targets. 2008; 8:160–165.
Article
12. Nakatsuji T, Liu YT, Huang CP, Zoubouis CC, Gallo RL, Huang CM. Antibodies elicited by inactivated Propionibacterium acnes-based vaccines exert protective immunity and attenuate the IL-8 production in human sebocytes: relevance to therapy for acne vulgaris. J Invest Dermatol. 2008; 128:2451–2457.
Article
13. Mussalem JS, Vasconcelos JR, Squaiella CC, Ananias RZ, Braga EG, Rodrigues MM, et al. Adjuvant effect of the Propionibacterium acnes and its purified soluble polysaccharide on the immunization with plasmidial DNA containing a Trypanosoma cruzi gene. Microbiol Immunol. 2006; 50:253–263.
Article
14. Lodes MJ, Secrist H, Benson DR, Jen S, Shanebeck KD, Guderian J, et al. Variable expression of immunoreactive surface proteins of Propionibacterium acnes. Microbiology. 2006; 152:3667–3681.
Article
15. Nakatsuji T, Liu YT, Huang CP, Zouboulis CC, Gallo RL, Huang CM. Vaccination targeting a surface sialidase of P. acnes: implication for new treatment of acne vulgaris. PLoS One. 2008; 3:e1551.
Article
16. Brüggemann H. Insights in the pathogenic potential of Propionibacterium acnes from its complete genome. Semin Cutan Med Surg. 2005; 24:67–72.
Article
17. Nakatsuji T, Tang DC, Zhang L, Gallo RL, Huang CM. Propionibacterium acnes CAMP factor and host acid sphingomyelinase contribute to bacterial virulence: potential targets for inflammatory acne treatment. PLoS One. 2011; 6:e14797.
Article
18. Lo CW, Lai YK, Liu YT, Gallo RL, Huang CM. Staphylococcus aureus hijacks a skin commensal to intensify its virulence: immunization targeting beta-hemolysin and CAMP factor. J Invest Dermatol. 2011; 131:401–409.
Article
19. Ozlu E, Karadag AS, Ozkanli S, Oguztuzun S, Kilic M, Zemheri E, et al. Comparison of TLR-2, TLR-4, and antimicrobial peptide levels in different lesions of acne vulgaris. Cutan Ocul Toxicol. 2016; 35:300–309.
Article
20. Górski A, Dąbrowska K, Hodyra-Stefaniak K, Borysowski J, Międzybrodzki R, Weber-Dąbrowska B. Phages targeting infected tissues: novel approach to phage therapy. Future Microbiol. 2015; 10:199–204.
Article
21. Katsuta Y, Iida T, Inomata S, Denda M. Unsaturated fatty acids induce calcium influx into keratinocytes and cause abnormal differentiation of epidermis. J Invest Dermatol. 2005; 124:1008–1013.
Article
22. Borovaya A, Dombrowski Y, Zwicker S, Olisova O, Ruzicka T, Wolf R, et al. Isotretinoin therapy changes the expression of antimicrobial peptides in acne vulgaris. Arch Dermatol Res. 2014; 306:689–700.
Article
23. Brüggemann H, Lood R. Bacteriophages infecting propionibacterium acnes. Biomed Res Int. 2013; 2013:705741.
24. Brown TL, Petrovski S, Dyson ZA, Seviour R, Tucci J. The formulation of bacteriophage in a semi solid preparation for control of Propionibacterium acnes growth. PLoS One. 2016; 10:e0151184.
Article
25. Esteban PP, Alves DR, Enright MC, Bean JE, Gaudion A, Jenkins AT, et al. Enhancement of the antimicrobial properties of bacteriophage-K via stabilization using oil-in-water nano-emulsions. Biotechnol Prog. 2014; 30:932–944.
Article
26. Chen LK, Liu LY, Hu A, Chang KC, Lin NT, Lai MJ, et al. Potential of bacteriophage ΦAB2 as an environmental biocontrol agent for the control of multidrug-resistant Acinetobacter baumannii. BMC Microbiol. 2013; 13:154.
Article